
## Carl V Asche

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3924797/publications.pdf Version: 2024-02-01



CADI V ΔSCHE

#	Article	IF	CITATIONS
1	Cost-effectiveness of Physical Therapy vs Intra-articular Glucocorticoid Injection for Knee Osteoarthritis. JAMA Network Open, 2022, 5, e2142709.	5.9	7
2	Society of Behavioral Medicine (SBM) position statement: support increased knowledge and efforts to address the financial burden associated with cancer treatment. Translational Behavioral Medicine, 2021, 11, 1289-1291.	2.4	2
3	Relation of Frailty to Cost for Patients Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 125, 469-474.	1.6	9
4	Evaluation of Intraoperative, Local Site Injections of Liposomal Bupivacaine as an Alternative to Standard Local Anesthetics in Patients Undergoing Total Hip Arthroplasty. Hospital Pharmacy, 2020, 55, 273-278.	1.0	1
5	Future of Data Analytics in the Era of the General Data Protection Regulation in Europe. Pharmacoeconomics, 2020, 38, 1021-1029.	3.3	7
6	Association Between Exposure of Ipratropium and Salmeterol and Diagnosis of Multiple Sclerosis: A Matched Case–control Study. Clinical Therapeutics, 2019, 41, 1477-1485.	2.5	1
7	Impact of liposomal bupivacaine on opioid use, hospital length of stay, discharge status, and hospitalization costs in patients undergoing total hip arthroplasty. Journal of Medical Economics, 2019, 22, 1253-1260.	2.1	8
8	Long-term effectiveness of a gambling intervention program among children in central Illinois. PLoS ONE, 2019, 14, e0212087.	2.5	4
9	Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. Journal of Comparative Effectiveness Research, 2019, 8, 393-402.	1.4	17
10	Impact of treatment with liposomal bupivacaine on hospital costs, length of stay, and discharge status in patients undergoing total knee arthroplasty at high-use institutions. Journal of Medical Economics, 2019, 22, 85-94.	2.1	10
11	Comparison of cost and outcomes in patients receiving thoracic epidural versus liposomal bupivacaine for video-assisted thoracoscopic pulmonary resection. American Journal of Surgery, 2019, 217, 520-524.	1.8	20
12	Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 1-7.	3.0	18
13	Communicating Value in Simulation: Cost–Benefit Analysis and Return on Investment. Academic Emergency Medicine, 2018, 25, 230-237.	1.8	36
14	Advance Care Planning in an Accountable Care Organization Is Associated with Increased Advanced Directive Documentation and Decreased Costs. Journal of Palliative Medicine, 2018, 21, 489-502.	1.1	44
15	Association between availability of care providers and healthcare utilizations among adults with asthma. Current Medical Research and Opinion, 2017, 33, 479-487.	1.9	1
16	Efficacy of <i>Bifidobacterium infantis 35624</i> in patients with irritable bowel syndrome: a meta-analysis. Current Medical Research and Opinion, 2017, 33, 1191-1197.	1.9	64
17	The benefits, risks and costs of privacy: patient preferences and willingness to pay. Current Medical Research and Opinion, 2017, 33, 845-851.	1.9	7
18	Evaluation of Healthcare Interventions and Big Data: Review of Associated Data Issues. Pharmacoeconomics, 2017, 35, 759-765.	3.3	24

CARL V ASCHE

#	Article	IF	CITATIONS
19	Cost-Effectiveness of Primary Care Management With or Without Early Physical Therapy for Acute Low Back Pain. Spine, 2017, 42, 285-290.	2.0	36
20	Allergies, antibiotics use, and multiple sclerosis. Current Medical Research and Opinion, 2017, 33, 1451-1456.	1.9	5
21	Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs. Journal of Medical Economics, 2017, 20, 1000-1006.	2.1	7
22	Local infiltration for postsurgical analgesia following total hip arthroplasty: a comparison of liposomal bupivacaine to traditional bupivacaine. Current Medical Research and Opinion, 2017, 33, 1283-1290.	1.9	31
23	Significant Improvement of Mobility Recovery in Acute Care Patients After Total Knee Arthroplasty With Liposomal Bupivacaine Injectable Suspension. Journal of Acute Care Physical Therapy, 2017, 8, 11-19.	0.2	3
24	Explaining the link between access-to-care factors and health care resource utilization among individuals with COPD. International Journal of COPD, 2016, 11, 357.	2.3	16
25	Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States. Value in Health, 2016, 19, 239-248.	0.3	7
26	Cost–benefit evaluation of liposomal bupivacaine in the management of patients undergoing total knee arthroplasty. American Journal of Health-System Pharmacy, 2016, 73, e247-e254.	1.0	35
27	Impact of bowel preparation type on the quality of colonoscopy: a multicenter community-based study. Journal of Community Hospital Internal Medicine Perspectives, 2016, 6, 31074.	0.8	8
28	Long-term risk of colorectal cancer by gender after positive colonoscopy: population-based cohort study. Current Medical Research and Opinion, 2016, 32, 1367-1374.	1.9	6
29	Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States. Journal of Medical Economics, 2015, 18, 600-611.	2.1	11
30	Epidemiology of Bacteremia in Previously Healthy Febrile Infants: A Follow-up Study. Hospital Pediatrics, 2015, 5, 293-300.	1.3	27
31	Su1537 Impact of Bowel Preparation Type on the Quality of Colonoscopy. Gastrointestinal Endoscopy, 2015, 81, AB320.	1.0	0
32	Early Physical Therapy vs Usual Care in Patients With Recent-Onset Low Back Pain. JAMA - Journal of the American Medical Association, 2015, 314, 1459.	7.4	123
33	Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting. Future Oncology, 2015, 11, 439-447.	2.4	4
34	Pairing Motivational Interviewing with a Nutrition and Physical Activity Assessment and Counseling Tool in Pediatric Clinical Practice: A Pilot Study. Childhood Obesity, 2014, 10, 432-441.	1.5	30
35	Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence. Journal of Medical Economics, 2014, 17, 626-636.	2.1	17
36	Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases. Applied Health Economics and Health Policy, 2014, 12, 547-557.	2.1	15

CARL V ASCHE

#	Article	IF	CITATIONS
37	Blood Culture Time to Positivity in Febrile Infants With Bacteremia. JAMA Pediatrics, 2014, 168, 844.	6.2	102
38	Review of Models Used in Economic Analyses of New Oral Treatments for TypeÂ2 Diabetes Mellitus. Pharmacoeconomics, 2014, 32, 15-27.	3.3	28
39	Systemic Therapy for Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in Nationally Representative US Claims Database. BioDrugs, 2014, 28, 229-236.	4.6	13
40	Efficacy, Patient-Reported Outcomes (PROs), and Tolerability of the Changing Therapeutic Landscape in Patients with Metastatic Prostate Cancer (MPC): A Systematic Literature Review. Value in Health, 2013, 16, 872-890.	0.3	15
41	Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials. Current Medical Research and Opinion, 2013, 29, 1287-1296.	1.9	19
42	Trends and predictors in methadone maintenance treatment dropout in Shanghai, China: 2005–2011. Current Medical Research and Opinion, 2013, 29, 731-738.	1.9	13
43	Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS–Kaposi's sarcoma. Journal of Medical Economics, 2013, 16, 606-613.	2.1	8
44	Impact of elevated intact parathyroid hormone on mortality and renal disease progression in patients with chronic kidney disease stages 3 and 4. Current Medical Research and Opinion, 2012, 28, 1527-1536.	1.9	9
45	Psychotropic-Related Hip Fractures: Meta-Analysis of First-Generation and Second-Generation Antidepressant and Antipsychotic Drugs. Annals of Pharmacotherapy, 2012, 46, 917-928.	1.9	84
46	Status Update of the Reimbursement Review Environment in the Public Sector across Four Latin American Countries. Value in Health Regional Issues, 2012, 1, 223-227.	1.2	8
47	Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. International Journal of COPD, 2012, 7, 201.	2.3	69
48	Prevalence and causes of dysphonia in a large treatmentâ€seeking population. Laryngoscope, 2012, 122, 343-348.	2.0	217
49	Direct health care costs of laryngeal diseases and disorders. Laryngoscope, 2012, 122, 1582-1588.	2.0	132
50	The impact of laryngeal disorders on workâ€related dysfunction. Laryngoscope, 2012, 122, 1589-1594.	2.0	74
51	Presence of central nervous system, cardiovascular and overall coâ€morbidity burden in patients with overactive bladder disorder in a realâ€world setting. BJU International, 2012, 109, 572-580.	2.5	40
52	A review of the efficacy and outcomes studies of currently approved chemotherapy treatments for advanced AIDS-Kaposi's sarcoma. HIV and AIDS Review, 2011, 10, 56-60.	0.2	1
53	Essentials of Pharmacoeconomics. Value in Health, 2011, 14, 616-617.	0.3	1
54	The Economic Burden of Dry Eye Disease in the United States: A Decision Tree Analysis. Cornea, 2011, 30, 379-387.	1.7	347

CARL V ASCHE

#	Article	IF	CITATIONS
55	A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes. Clinical Therapeutics, 2011, 33, 74-109.	2.5	342
56	Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data. Journal of Bone and Mineral Metabolism, 2011, 29, 193-200.	2.7	10
57	RAISE (Rapid Access Integrating Safer Entry) for the Elderly: Readiness of Older Adults to Adopt a Universal Serial Bus Personal Health Record for Medication Reconciliation. Ageing International, 2011, 36, 295-302.	1.3	1
58	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV. Value in Health, 2010, 13, 18-24.	0.3	22
59	The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder. Current Medical Research and Opinion, 2010, 26, 1843-1853.	1.9	34
60	An economic evaluation of therapeutic alteration in the management of insomnia. Current Medical Research and Opinion, 2009, 25, 663-669.	1.9	5
61	Evaluation of Adverse Events of Oral Antihyperglycaemic Monotherapy Experienced by a Geriatric Population in a Real-World Setting. Drugs and Aging, 2008, 25, 611-622.	2.7	16
62	Risk Estimates of Hysterectomy and Selected Conditions Commonly Treated with Hysterectomy. Annals of Epidemiology, 2008, 18, 253-260.	1.9	56
63	Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 2008, 61, 1162-1168.	3.0	32
64	Diabetes and Associated Risk Factors in Patients Referred for Physical Therapy in a National Primary Care Electronic Medical Record Database. Physical Therapy, 2008, 88, 1408-1416.	2.4	23
65	Assessment of COPD-related outcomes via a national electronic medical record database. International Journal of COPD, 2008, Volume 3, 323-326.	2.3	14
66	Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid. Archives of Gynecology and Obstetrics, 2007, 276, 211-218.	1.7	5
67	ASSESSMENT OF PHYSICIAN PRESCRIBING FOR PRIMARY CARE PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A NATIONAL ELECTRONIC MEDICAL RECORD (EMR) RESEARCH DATABASE. Chest, 2006, 130, 175S.	0.8	4
68	Meta-analysis of bacterial resistance to macrolides—providing generalizable results: authors' response. Journal of Antimicrobial Chemotherapy, 2005, 56, 434-435.	3.0	1
69	Meta-analysis of bacterial resistance to macrolides. Journal of Antimicrobial Chemotherapy, 2005, 55, 748-757.	3.0	28
70	Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Current Medical Research and Opinion, 2004, 20, 739-747.	1.9	25
71	Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. Current Medical Research and Opinion, 2004, 20, 969-980.	1.9	14
72	Treatment Costs of Community-Acquired Pneumonia in an Employed Population. Chest, 2004, 125, 2140-2145.	0.8	113

#	Article	IF	CITATIONS
73	The economic cost of otitis media in Canada. International Journal of Pediatric Otorhinolaryngology, 1999, 49, 27-36.	1.0	31